Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | PDE4A | P27815 | 4/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.46 |
| ▸ | PDE4C | Q08493 | 4/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | BRD2 | P25440 | 1/20 | 0.43 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.43 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15931519 | 1.00 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL7033933 | 0.95 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL18256061 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL18256051 | 0.90 | SMN1; SMN2 (0.57) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL17314877 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL17314878 | 0.89 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL18256135 | 0.89 | SMN1; SMN2 (0.56) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL15923932 | 0.86 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL17314452 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPK1CYP3A4PMP22POLB | |
| SCHEMBL17314451 | 0.86 | SMN1; SMN2 (0.51) | SMN1; SMN2MAPK1CYP3A4PMP22POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2951180-B1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME (US) | 2018-05-02 | — | — | EP | disclosed |
| US-9682978-B2 | 2,6,7 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9540377-B2 | 2,6,7,8 substituted purines as HDM2 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150368247-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150368247-A1 | 2,6,7 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, NSUN2, DHX29 | SMN1; SMN2 1914/4885MAPK1 2543/4885CYP3A4 4143/4885 |
| US-20150353553-A1 | 2,6,7,8 SUBSTITUTED PURINES AS HDM2 INHIBITORS | DDX21, DPYD, NSUN2 | SMN1; SMN2 2062/4885MAPK1 2502/4885CYP3A4 4109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.